Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

Understand the regulatory and policy considerations for running clinical trial recruitment campaigns on nontraditional or ...

Learn how demographic and behavioral insights inform platform-specific messaging, creative formats, and call-to-action ...

In today’s ACT Brief, we look at how Trialbee evaluates nontraditional digital platforms for patient recruitment, review new ...

Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient ...

ACT: At this year’s SCRS Summit, several site representatives raised concerns about overly complex protocols and patient ...

Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok ...

In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s ...

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...